Literature DB >> 11996419

Venomous snakebites in the United States: management review and update.

Gregory Juckett1, John G Hancox.   

Abstract

Venomous snakebites, although uncommon, are a potentially deadly emergency in the United States. Rattlesnakes cause most snakebites and related fatalities. Venomous snakes in the United States can be classified as having hemotoxic or neurotoxic venom. Patients with venomous snakebites present with signs and symptoms ranging from fang marks, with or without local pain and swelling, to life-threatening coagulopathy, renal failure, and shock. First-aid techniques such as arterial tourniquets, application of ice, and wound incisions are ineffective and can be harmful; however, suction with a venom extractor within the first five minutes after the bite may be useful. Conservative measures, such as immobilization and lymphatic constriction bands, are now advocated until emergency care can be administered. Patients with snakebites should undergo a comprehensive work-up to look for possible hematologic, neurologic, renal, and cardiovascular abnormalities. Equine-derived antivenin is considered the standard of care; however, a promising new treatment is sheep-derived antigen binding fragment ovine (CroFab), which is much less allergenic. Although there is no universal grading system for snakebites, a I through IV grading scale is clinically useful as a guide to antivenin administration. Surgical intervention with fasciotomy is now reserved for rare cases. Snakebite prevention should be taught to patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996419

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  16 in total

1.  The management of pit viper envenomation of the hand.

Authors:  Mehmet Bozkurt; Yalcin Kulahci; Fatih Zor; Emin Kapi
Journal:  Hand (N Y)       Date:  2008-05-28

2.  Early morning neuroparalytic syndrome.

Authors:  Mohammed Haneef; Donae E George; Abraham S Babu
Journal:  Indian J Pediatr       Date:  2009-10       Impact factor: 1.967

3.  Severe coagulopathy after a massasauga rattlesnake bite.

Authors:  Marissa Laureano; Mark Crowther
Journal:  CMAJ       Date:  2018-02-20       Impact factor: 8.262

4.  Opossum peptide that can neutralize rattlesnake venom is expressed in Escherichia coli.

Authors:  Claire F Komives; Elda E Sanchez; Anurag S Rathore; Brandon White; Michael Balderrama; Montamas Suntravat; Angela Cifelli; Varsha Joshi
Journal:  Biotechnol Prog       Date:  2016-12-01

5.  Epidemiology of non-canine bite and sting injuries treated in U.S. emergency departments, 2001-2004.

Authors:  Mary Elizabeth O'Neil; Karin Ann Mack; Julie Gilchrist
Journal:  Public Health Rep       Date:  2007 Nov-Dec       Impact factor: 2.792

Review 6.  Inhibition of hemorragic snake venom components: old and new approaches.

Authors:  Isabella Panfoli; Daniela Calzia; Silvia Ravera; Alessandro Morelli
Journal:  Toxins (Basel)       Date:  2010-03-25       Impact factor: 4.546

7.  Case Report: Safe Tourniquet Removal in Black Mamba (Dendroaspis polylepis) Bites.

Authors:  Ratang Pholosho Pelle; Andreas Engelbrecht; Vidya Lalloo
Journal:  Am J Trop Med Hyg       Date:  2021-11-01       Impact factor: 3.707

8.  α-Gal on Crotalidae-polyvalent Fab antivenom (CroFab): Investigating the relevance to immediate hypersensitivity reactions.

Authors:  Matthew Straesser; Behnam Keshavarz; Larry Borish; Dilawar Khokhar; Angela Holian; Nathan P Charlton; Thomas A E Platts-Mills; Jeffrey M Wilson
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10-27

Review 9.  Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat.

Authors:  Masashi Mizuno; Yasuhiko Ito; B Paul Morgan
Journal:  Mar Drugs       Date:  2012-07-23       Impact factor: 6.085

10.  The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths.

Authors:  Anuradhani Kasturiratne; A Rajitha Wickremasinghe; Nilanthi de Silva; N Kithsiri Gunawardena; Arunasalam Pathmeswaran; Ranjan Premaratna; Lorenzo Savioli; David G Lalloo; H Janaka de Silva
Journal:  PLoS Med       Date:  2008-11-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.